217 related articles for article (PubMed ID: 24032045)
1. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study.
Liang J; Jiang MJ; Deng X; Xiao Zhou X
Hepat Mon; 2013; 13(6):e7862. PubMed ID: 24032045
[TBL] [Abstract][Full Text] [Related]
2. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
[TBL] [Abstract][Full Text] [Related]
3. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
4. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
6. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
7. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis.
Liu H; Wang X; Wan G; Yang Z; Zeng H
Am J Med Sci; 2014 Feb; 347(2):131-8. PubMed ID: 23563307
[TBL] [Abstract][Full Text] [Related]
8. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.
Shamliyan TA; MacDonald R; Shaukat A; Taylor BC; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL; Wilt TJ
Ann Intern Med; 2009 Jan; 150(2):111-24. PubMed ID: 19124812
[TBL] [Abstract][Full Text] [Related]
10. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
12. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
13. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
14. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis.
Wang N; Hu HD; Sun H; Feng Q; Hu P; Liu Q; Ren H
Turk J Gastroenterol; 2013; 24(3):230-40. PubMed ID: 24226716
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
17. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]